Apyx Medical Corp expected to post a loss of 19 cents a share - Earnings Preview

Apyx Medical

06/11/2024 14:12

* Apyx Medical Corp  APYX.OQ   APYX.O  is expected to show a
fall
in quarterly revenue when it reports  results on November 8 for
the period ending September 30 2024
    * The Clearwater Florida-based  company is expected to
report a
5.0% decrease in revenue to $11.378 million from $11.98 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Apyx Medical Corp is for
a
loss of 19 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Apyx
Medical Corp
is $2.50​, above​ its last closing price of $1.17. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.20       -0.20      -0.19     Beat    4.1
 Mar. 31 2024  -0.22       -0.21      -0.22     Missed  -2.6
 Dec. 31 2023  -0.20       -0.18      -0.28     Missed  -57.7​
 Sep. 30 2023  -0.12       -0.11      -0.13     Missed  -14.8
 ​​Jun.        -0.07       -0.07      -0.11     Missed  -58.5
 30 2023                                                
 Mar. 31 2023  -0.16       -0.13      -0.10     Beat    25.9​
 Dec. 31 2022  -0.15       -0.14      -0.17     Missed  -19.3
 Sep. 30 2022  -0.15       -0.14      -0.17     Missed  -17.2
 This summary was machine generated November 6 at 14:11 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)